Search 

ACON Pharmaceuticals Inc. (ACON Pharma) is a specialty pharmaceutical company and focuses on siRNA and mRNA nanoparticle delivery, 505(b)(2) NDA, and complex ANDA drug product development with its captive drug delivery system and technology platforms. Acon Pharma is a privately held corporation located in Princeton, New Jersey, USA. As a dynamic pharmaceutical company in a vibrant life science research region, Acon Pharma leverages the expertise and experience of highly skilled, multi-disciplinary workforce to accelerate the product development of complex drug delivery systems. The Company’s key managers were primarily educated in US with advanced degrees and trained in the pharmaceutical industry for many years, and have possessed deep professional knowledge, technical know-how, and extensive experiences in pharmaceutical product development.

We are currently raising 5 million dollar fund to support IND-enabling studies for our patented liposomal siRNA for treatment of pulmonary fibrosis and long-acting microsphere for treatment of schizophrenia. We are also developing delayed release nanoemulsion for osteoporosis, and sustained release gel for fungal infection.

Private equity firm

Manufacturing company

国家纳米科学院与广东

Investor

Founded in 2005, Baiyu is dedicated to R&D, manufacturing and marketing high-quality pharmaceutical products and APIs to all patients. As an innovation-based pharmaceutical company, we are specializing in chemical/botanical/biological medicinal products, especially ginkgo pharmaceutical products. And in 2020, aiming to protect everyone’s healthcare, Baiyu has built own subsidiary to produce high quality of Personal Protective Equipment to worldwide market.

With more than 1,300 employees and 8 wholly owned subsidiaries, Baiyu has a rich pipeline of products launched for neuropsychiatric, cardio-cerebrovascular, anti-tumor, respiratory, digestive, anti-infective areas along with many products under development. And Ginkgolide injection is the first innovative botanical injectable approved since the implementation of Drug Registration Regulation (2007), of which the active ingredient contents reach up to 99%.

Currently, several production lines have obtained GMP certificates, and new factories meeting EU&US GMP requirements with fully automatic and intelligent operations have been built to accelerate Baiyu’s globalization process.

China医药创新促进会（原名“China医药工业科研开发促进会”,简称“China药促会”）,英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA）,成立于1988年,是经国家民政部登记注册的非营利性全国性4A级社会组织。
China药促会秉承“创新、产业化、国际化”的宗旨,以临床需求为导向,长期致力于“产学研用资”紧密结合,促进医药行业创新发展,已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台,目前有会员单位144家。China药促会已成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会和创新研发服务专业委员会,形成了以创新为核心,以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架,并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。

A human-genetics driven next generation immunity-oncology company

Life Science and Healthcare Venture Capital Investor